ANDO DALE G 4
4 · SANGAMO BIOSCIENCES INC · Filed Dec 28, 2012
Insider Transaction Report
Form 4
ANDO DALE G
VP, Therapeutic Dev. & CMO
Transactions
- Sale
Common Stock
2012-12-26$5.94/sh−2,000$11,888→ 88,798 total - Exercise/Conversion
Common Stock
2012-12-26$3.61/sh+15,000$54,150→ 103,798 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2012-12-26−15,000→ 35,800 totalExercise: $3.61Exp: 2014-08-01→ Common Stock (15,000 underlying) - Sale
Common Stock
2012-12-26$5.92/sh−15,000$88,830→ 88,798 total
Footnotes (5)
- [F1]The sales reported in this Form 4 were effected pursuant to the Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2012, amended on September 12, 2012.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.9033 to $5.9633, inclusive. The Reporting Person undertakes to provide to Sangamo Biosciences Inc., any security holder of Sangamo Biosciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4) to this Form 4.
- [F3]Includes 35,000 shares subject to Restricted Stock Units, which will vest in a series of three successive equal annual installments upon the Reporting Person's completion of each year of service over the three year period from the grant date.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.8501 to $5.97, inclusive. The Reporting Person undertakes to provide to Sangamo Biosciences Inc., any security holder of Sangamo Biosciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4) to this Form 4.
- [F5]All shares underlying this option are vested and immediately exercisable.